These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35764968)

  • 1. Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions.
    Shetty SS; Krumerman A
    Cardiovasc Diabetol; 2022 Jun; 21(1):119. PubMed ID: 35764968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Metab; 2022 Nov; 48(6):101390. PubMed ID: 36170946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.
    Li J; Yu Y; Sun Y; Yu B; Tan X; Wang B; Lu Y; Wang N
    Cardiovasc Diabetol; 2023 Oct; 22(1):278. PubMed ID: 37848934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Zheng RJ; Wang Y; Tang JN; Duan JY; Yuan MY; Zhang JY
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):e145-e152. PubMed ID: 34813574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis.
    Ong HT; Teo YH; Teo YN; Syn NL; Wee CF; Leong S; Yip ASY; See RM; Ting AZH; Chia AZ; Cheong AJY; Tan BY; Ho JS; Yeo LL; Leow AS; Yeo TC; Wong RC; Chai P; Kojodjojo P; Sia CH
    J Stroke Cerebrovasc Dis; 2022 Jan; 31(1):106159. PubMed ID: 34689051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors.
    Tanaka H; Tatsumi K; Matsuzoe H; Soga F; Matsumoto K; Hirata KI
    Int J Cardiovasc Imaging; 2021 Apr; 37(4):1333-1341. PubMed ID: 33392879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment on "Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients".
    Lai SW
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):201-202. PubMed ID: 38008854
    [No Abstract]   [Full Text] [Related]  

  • 11. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus.
    Fauchier L; Boriani G; de Groot JR; Kreutz R; Rossing P; Camm AJ
    Europace; 2021 Dec; 23(12):1873-1891. PubMed ID: 34411235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
    Okunrintemi V; Mishriky BM; Powell JR; Cummings DM
    Diabetes Obes Metab; 2021 Jan; 23(1):276-280. PubMed ID: 33001548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.
    Vrachatis DA; Papathanasiou KA; Iliodromitis KE; Giotaki SG; Kossyvakis C; Raisakis K; Kaoukis A; Lambadiari V; Avramides D; Reimers B; Stefanini GG; Cleman M; Giannopoulos G; Lansky A; Deftereos SG
    Drugs; 2021 Aug; 81(12):1381-1395. PubMed ID: 34297330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
    Perry RJ; Shulman GI
    J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue.
    Packer M
    Cardiovasc Diabetol; 2019 Sep; 18(1):121. PubMed ID: 31551089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus.
    Granger CB; Mahaffey KW
    Circulation; 2020 Apr; 141(15):1235-1237. PubMed ID: 32282249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.